Beam Therapeutics (BEAM) presented additional data from the Phase 1/2 clinical trial of BEAM-302 in patients with alpha-1 antitrypsin deficiency, AATD, at the 2025 Alpha-1 Foundation 7th Global ...

Scotiabank analyst Greg Harrison maintained a Buy rating on Beam Therapeutics (BEAM – Research Report) today and set a price target of $40.00. The company’s shares closed last Friday at $15.27.

over 6000 assets (including all Forex pairs, Cryptocurrencies, Commodities, Indices and US stocks) unique interbank rates extensive historic data the option to save your configuration Here below ...